Biotech

Five companies now dominate the conversation around AI-designed medicine, and in the past seven months, three of them have hit milestones that used to take a decade: a Hong Kong stock exchange debut, a Nasdaq IPO, and a $2.1 billion funding round. This is a side-by-side look at where the leading AI drug discovery companies … Read more

📌 TL;DR — Executive Summary What Changed: On July 1, 2026, the FDA expanded Casgevy’s approval from age 12+ down to age 2+. Why It Matters: This instantly adds ~5,500 eligible U.S. patients across 75+ authorized treatment centers. The Core Pivot: Because each autologous dose is custom-made from a patient’s own cells, manufacturing infrastructure—not drug … Read more

Key Summary As of 2026, AI Drug Discovery has moved past the “era of hypothesis” and into the “era of clinical proof.” The clearest example is Insilico Medicine’s Rentosertib, a drug candidate whose target discovery and molecular design were both AI-driven, which entered Phase 3 clinical trials in July 2026 for idiopathic pulmonary fibrosis (IPF). … Read more

Stage 4 Breast Cancer and ADC — How Enhertu and Trodelvy Altered Survival Curves From HER2-Low Breast Cancer to Triple Negative Breast Cancer, looking at the current state of metastatic breast cancer treatment through Overall Survival and Progression-Free Survival data Stage 4 Breast Cancer (metastatic breast cancer) carries widely differing prognoses even within the same … Read more

💡 Key Takeaways Catalent’s Structural Shift: Novo Holdings finalized its acquisition in December 2024. In the process, three pivotal sterile fill-finish sites transferred directly to Novo Nordisk. This immediately raised concerns over strategic independence, and prompted several global pharma peers to diversify their sourcing. PCI Pharma’s Windfall Advantage: PCI Pharma is aggressively executing a $1 … Read more

The World’s First Synthetic Cell: How SpudCell Could Transform Drug Discovery, ADC and Biomanufacturing SpudCell is the world’s first synthetic cell assembled entirely from nonliving molecules that can grow, replicate, and divide through an engineered cell cycle. On July 1, 2026, researchers at the University of Minnesota led by Professors Kate Adamala and Aaron Engelhart … Read more

The boundaries between the global biopharmaceutical industry and information technology are completely dissolving, triggering a massive paradigm shift. Most notably, as clinical data for revolutionary new therapies are unveiled, a structural alignment is emerging where artificial intelligence technologies—such as OpenAI and deep learning—are integrated to analyze and validate these findings. Consequently, this comprehensive analysis explores … Read more

For decades, the greatest contradiction dominating the global pharmaceutical and healthcare market has been the critical question: “Why do drug prices continuously skyrocket for patients when drug manufacturing technology is advancing so brilliantly day by day?” To address this issue, this analysis explores the multi-layered inefficiencies of the distribution supply chain. Furthermore, we examine how … Read more

A wave of 2026 headlines has put one question in the spotlight: could an everyday acne cream be quietly degrading into a carcinogen? The CeraVe benzene cancer lawsuit driving that concern is only part of a broader story in global healthcare and consumer safety this year — alongside genuine clinical milestones in treating historically “undruggable” … Read more

The global oncology landscape is undergoing a seismic shift. For the past decade, immune checkpoint inhibitors targeting the PD-1 and PD-L1 pathways have been the undisputed titans of cancer care. Heavyweights like Merck’s Keytruda have rewritten the survival curves for millions. However, as monotherapy reaches its therapeutic ceiling—particularly in aggressive, “cold” microenvironments—the biopharma industry is … Read more